These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 22101066)

  • 21. Coping with antibiotic resistance: the impending crisis.
    Gould IM
    Int J Antimicrob Agents; 2010 Nov; 36 Suppl 3():S1-2. PubMed ID: 21129626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are we eliminating cures with antibiotic abuse? A study among dentists.
    Goud SR; Nagesh L; Fernandes S
    Niger J Clin Pract; 2012; 15(2):151-5. PubMed ID: 22718162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial resistance: action to combat the rising microbial challenges.
    Paphitou NI
    Int J Antimicrob Agents; 2013 Jun; 42 Suppl():S25-8. PubMed ID: 23684003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2012 and beyond: potential for the start of a second pre-antibiotic era?
    Appelbaum PC
    J Antimicrob Chemother; 2012 Sep; 67(9):2062-8. PubMed ID: 22687888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovation - drugs and diagnostics.
    Finch R
    J Antimicrob Chemother; 2007 Aug; 60 Suppl 1():i79-82. PubMed ID: 17656390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel systemic antibiotics in dermatology.
    Atanaskova Mesinkovska N; Tomecki KJ
    Dermatol Ther; 2012; 25(1):1-5. PubMed ID: 22591494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
    Falagas ME; Fragoulis KN; Karydis I
    PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The need for new antibiotics.
    Livermore DM
    Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():1-9. PubMed ID: 15522034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economics of antibiotic resistance.
    Sipahi OR
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.
    Chopra I; Schofield C; Everett M; O'Neill A; Miller K; Wilcox M; Frère JM; Dawson M; Czaplewski L; Urleb U; Courvalin P
    Lancet Infect Dis; 2008 Feb; 8(2):133-9. PubMed ID: 18222164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [International strategies and campaigns to promote the prudent use of antibiotics by health professionals and patients].
    Campos J; Pérez-Vázquez M; Oteo J
    Enferm Infecc Microbiol Clin; 2010 Nov; 28 Suppl 4():50-4. PubMed ID: 21458702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accelerating resistance, inadequate antibacterial drug pipelines and international responses.
    Theuretzbacher U
    Int J Antimicrob Agents; 2012 Apr; 39(4):295-9. PubMed ID: 22341298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial resistance: no action today, no cure tomorrow.
    Sharma A
    Indian J Med Microbiol; 2011; 29(2):91-2. PubMed ID: 21654100
    [No Abstract]   [Full Text] [Related]  

  • 35. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irrational use of antibiotics and role of the pharmacist: an insight from a qualitative study in New Delhi, India.
    Kotwani A; Wattal C; Joshi PC; Holloway K
    J Clin Pharm Ther; 2012 Jun; 37(3):308-12. PubMed ID: 21883328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antibiotics in primary care].
    Steciwko A; Lubieniecka M; Muszyńska A
    Pol Merkur Lekarski; 2011 May; 30(179):323-6. PubMed ID: 21675133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.